Neoadjuvant 5-fluorouracil, Epirubicin & Cyclophosphamide (FEC) Followed

See also
Status	Clinical Trial	Phase
Completed	`NCT01305941` - A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases	Phase 2
Completed	`NCT01432223` - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab	Phase 2
Completed	`NCT01433926` - Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years	N/A
Recruiting	`NCT05871918` - A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer	Phase 3
Terminated	`NCT02598310` - Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT02568839` - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer	Phase 2/Phase 3
Completed	`NCT02675231` - A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer	Phase 2
Terminated	`NCT02154529` - Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT01565200` - HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1	Phase 2
Active, not recruiting	`NCT02947685` - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer	Phase 3
Completed	`NCT02066532` - Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	Phase 1/Phase 2
Completed	`NCT01677455` - An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer	Phase 2
Completed	`NCT01583426` - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)	Phase 3
Withdrawn	`NCT01361945` - AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT02326974` - T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA	Phase 2
Not yet recruiting	`NCT04644406` - PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Terminated	`NCT02131506` - A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer	Phase 1
Completed	`NCT00788931` - A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer	Phase 1
Completed	`NCT02488564` - A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer	Phase 2
Completed	`NCT02492711` - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	Phase 3

NCT number	NCT01340430
Study type	Interventional
Source	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Contact
Status	Completed
Phase	Phase 2
Start date	March 2011
Completion date	January 2022

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms